Current therapies for chronic obstructive pulmonary disease (COPD) alleviate symptoms, but do not deal with disease progression. Respiratory mucus is primarily made up of mucins, of which mucin 5AC (MUC5AC) is the most predominant in COPD. It was hypothesized that mitochondria may control the expression of MUC5AC in COPD airway epithelium by modulating intracellular reactive oxygen species (ROS) levels.
Upstream Bio Inc.’s favorable top-line results from the phase II Valiant trial testing verekitug in adults with severe asthma were not enough to charm Wall Street, and shares of the firm (NASDAQ:UPB) closed Feb. 11 at $14.69, down $13.12, or 47%.
Australian respiratory imaging technology company 4dmedical Ltd. raised AU$150 million (US$105 million) in an institutional placement to accelerate U.S. adoption of its CT:VQ lung imaging software to bolster the company’s lead in software-based lung imaging.
